Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic intravenous mesenchymal stromal cells for children with recessive dystrophic epidermolysis bullosa
ISRCTN46615946Phase 2Completed
- Sponsor
- King's College London
- Start
- Jun 2013
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by King's College London. Primary endpoint: Safety of allogeneic intravenously administered mesenchymal stromal cells over 12 months. Started Jun 2013; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on ISRCTN46615946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46615946.